Genocea biosciences, inc. (GNCA)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Grant revenue

-

-

-

235

670

308

731

1,977

Operating expenses:
Research and development

26,952

25,209

39,204

34,645

28,049

23,727

15,695

11,240

General and administrative

12,037

14,309

13,433

15,427

13,987

9,747

4,961

3,690

Restructuring costs

-

-

2,618

0

0

-

-

-

Refund of research and development expense

-

-

-

1,592

0

0

-

-

Total operating expenses

38,989

39,518

55,255

48,480

42,036

33,474

20,656

14,930

Loss from operations

-38,989

-39,518

-55,255

-48,245

-41,366

-33,166

-19,925

-12,953

Other income (expense):
Change in fair value of warrants

986

14,757

0

-

-

-

-

-

Other expense

-

-

-

410

163

55

-

-

Interest expense, net

946

1,021

1,441

1,738

1,280

1,025

-

-

Other income (expense)

-1

-2,029

-14

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

725

222

-93

Loss on debt extinguishment

-

-

-

-

-

-435

-200

-

Interest expense, net

-

-

-

-

-

-

-459

-507

Total other income (expense)

39

11,707

-1,455

-1,328

-1,117

-2,130

-881

-414

Net loss

-38,950

-27,811

-56,710

-49,573

-42,483

-35,296

-20,806

-13,367

Unrealized loss on available-for-sale securities

-

-

-

-

-

180

1,605

1,781

Unrealized loss on available-for-sale securities

-

-

-

0

7

7

-

-

Comprehensive loss

-38,950

-27,811

-56,710

-49,573

-42,490

-35,303

-

-13,367

Net loss

-38,950

-27,811

-56,710

-49,573

-42,483

-35,296

-20,806

-13,367

Net loss attributable to common stockholders

-

-

-

-

-

-35,476

-22,411

-15,148

Net loss per share - basic and diluted

-1.89

-2.69

-1.98

-1.75

-1.74

-2.27

-75.46

-51.35

Weighted-average number of common shares used in computing net loss per share (in shares)

20,644

10,321

28,603

28,299

24,460

15,618

297

295